Agios Pharmaceuticals at Morgan Stanley Global Healthcare Conference Read more about Agios Pharmaceuticals at Morgan Stanley Global Healthcare Conference
Agios Reports Second Quarter 2017 Financial Results Read more about Agios Reports Second Quarter 2017 Financial Results
Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017 Read more about Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017
FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation Read more about FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation
Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 Read more about Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017
New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML Read more about New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML
Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency Read more about Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency
Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation Read more about Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma Read more about Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma
Agios Appoints David Scadden, M.D., to the Board of Directors Read more about Agios Appoints David Scadden, M.D., to the Board of Directors